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Simple Summary: The long-term follow-up and the results of the analysis of clinical, pathological 
and molecular prognostic factors for 420 children, adolescents and young adults affected by 
anaplastic large cell lymphoma (ALCL), enrolled in the international ALCL99 trial, were reported. 
The 10-year follow-up highlighted a progression free survival of 70% and an overall survival of 90%; 
rare late relapses occurred and no secondary malignancies were registered. Among clinical and 
pathological characteristics, only morphology including the small cell/lymphohistiocytic (SC/LH) 
pattern was independently associated with the risk of disease progression or relapse. When 
available minimal disseminated disease (MDD) data (n = 162) were included, both SC/LH pattern 
and MDD positivity resulted significantly associated with a poorer outcome when assessed by 
multivariate analysis. Considering MDD and SC/LH results, three biological/pathological risk 
groups with significantly different prognoses were identified. These results should be considered 
in the design of future ALCL trials to tailor individual treatments. 
Abstract: With the aim of describing the long-term follow-up and to define the prognostic role of 
the clinical/pathological/molecular characteristics at diagnosis for childhood, adolescent and young 
adults affected by anaplastic large cell lymphoma (ALCL), we analyzed 420 patients aged up to 22 
years homogeneously treated within the international ALCL99 trial. The 10-year progression free 
survival (PFS) was 70% and overall survival was 90%, rare late relapses occurred but no secondary 
malignancies were reported. Among clinical/pathological characteristics, only patients presenting a 
small cell/lymphohistiocytic (SC/LH) pattern were independently associated with risk of failure 
(hazard ratio = 2.49). Analysis of minimal disseminated disease (MDD), available for 162 patients, 
showed that both SC/LH pattern (hazard ratio = 2.4) and MDD positivity (hazard ratio = 2.15) were 
significantly associated with risk of failure in multivariate analysis. Considering MDD and SC/LH 
results, patients were separated into three biological/pathological (bp) risk groups: a high-risk 
group (bpHR) including MDD-positive patients with SC/LH pattern; a low-risk group (bpLR) 
including MDD-negative patients without SC/LH pattern; and an intermediate-risk group (bpIR) 
including remaining patients. The 10-year PFS was 40%, 75% and 86% for bpHR, bpIR and bpLR, 
respectively (p < 0.0001). These results should be considered in the design of future ALCL trials to 
tailor individual treatments. 
Keywords: ALCL; childhood; MDD; long-term follow-up 
 
1. Introduction 
Anaplastic large cell lymphoma (ALCL) accounts for 15% of pediatric and adolescent non-
Hodgkin lymphomas (NHLs) [1]. ALCL in children is nearly universally positive for Anaplastic 
Lymphoma Kinase (ALK) and in almost all cases is characterized by the t(2;5)(p23;q35) translocation, 
resulting in expression of the hybrid oncogenic tyrosine kinase NPM-ALK [2]. 
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Mediastinal involvement, visceral involvement defined as lung, liver or spleen involvement and 
skin lesions have previously been identified as poor prognostic factors [3]. In addition, progression 
free survival (PFS) and overall survival (OS) were significantly lower for patients with at least one 
clinical risk factor (61% and 73%, respectively) compared to patients without risk factors (89% and 
94%, respectively) [3]. These factors were used for patient stratification in the first randomized ALCL 
clinical trial of the European Inter-Group for Childhood Non-Hodgkin lymphoma (EICNHL), the 
ALCL99 trial [4,5]. The results of survival analysis at 2 years showed the event free survival (EFS) to 
range from 70% to 75%, without a significant difference between the randomized arms [4,5]. So far, 
data regarding survival of children with ALCL have only been reported at 2 or 5 years [3–11] with 
long-term follow-up never previously reported. Long-term follow-up data for ALCL patients after 
standard chemotherapy is needed for the design of new therapeutic trials and to judge the risk of late 
relapse. 
Several biological and pathologic characteristics have been shown to be associated with a higher 
risk of treatment failure in childhood ALK-positive ALCL over the past 15 years, i.e., high risk 
morphological pattern by the presence of a small cell (SC) or lymphohistiocytic (LH) pattern [12], 
positive PCR for NPM-ALK in peripheral blood (PB) and/or bone marrow (BM) at diagnosis (minimal 
disseminated disease; MDD) [13,14] and low anti-ALK antibody titers at diagnosis [15,16]. However, 
all these analyses were based on different cohorts, or evaluated by one or two collaborative 
international groups. 
The aim of the present study was to describe the long-term, 10-year follow-up of children, 
adolescents and young adults (CAYA) with ALCL and to confirm a prognostic role for the clinical, 
pathological and molecular characteristics available at diagnosis of the large group of patients treated 
within the ALCL99 protocol for systemic ALCL, and to better define risk stratification. 
2. Methods 
2.1. Patients and Clinical-Pathological Factors 
Between November 1999 (start of the study) and June 2006 (end of accrual in the randomized 
trial), 529 patients aged <22 years with a diagnosis of ALCL were registered to the ALCL99 trial, 
which was conducted by 10 national or cooperative groups including European and Japanese 
pediatric/lymphoma study groups (NCI NCT00006455). The study was approved by local ethics 
committees and informed consent was obtained from all patients/guardians. 
The diagnosis of ALCL was based on morphologic and immunophenotypic characteristics 
including CD30 and ALK immunostaining and, whenever possible, by molecular definition 
(evidence of ALK fusion genes for ALK + ALCL). Each national histologic diagnosis was reviewed 
by an international panel of 10 hematopathologists to confirm diagnosis and to define a consensus 
on morphological pattern ensuring high quality of the final classification [12]. 
Patients were staged according to the Ann Arbor and St Jude staging systems [17,18]. Patients 
were classified into clinical risk groups as high-risk (HR) if they presented with skin, mediastinal or 
visceral involvement (defined as lung, liver or spleen involvement), or as standard-risk (SR) if they 
had none of the previous sites of disease, or as low-risk (LR) if they were in stage I with completely 
resected disease. Patients with isolated skin lesions (most often CD30-positive cutaneous 
lymphoproliferations) or with CNS involvement were not eligible for the randomized study but 
registered in the database. Patients with CNS involvement were recently described [19]. Treatment 
and response criteria for all eligible patients were conducted according to the ALCL99 protocol (Table 
S1) [4,5]. 
2.2. Minimal Disseminated Disease (MDD) 
MDD was measured by qualitative PCR for NPM-ALK in BM or PB as previously described [16]. 
A patient was considered MDD-positive if at least one of the two samples (BM or PB) was PCR-
positive. Quality control was performed between EICNHL central laboratories demonstrating 
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identical results with serially diluted NPM-ALK-positive cell lines and blinded patient samples [16]. 
MDD analysis was not mandatory and was only performed in a few select laboratories of the 
participating countries. 
2.3. Statistical Analysis 
The first prognostic factor analysis was performed for all patients included in the database 
except those with isolated skin lesions or with CNS involvement (who were registered but received 
different treatments). Variables included in the analysis of prognostic factors were (i) clinical 
characteristics (age, sex, B-symptoms, lymph node, mediastinal involvement, skin lesions, bone and 
BM involvement, soft tissue mass, visceral, spleen, liver and lung involvement and lactate 
dehydrogenase (LDH) serum level); (ii) pathological data including ALK immunostaining, CD3 
expression and morphological patterns classified into two categories: ALCL with or without an SC 
or LH pattern (defined as the presence of either SC or LH morphological patterns whether or not 
these were associated with another morphological pattern); (iii) staging system: St Jude classification, 
Ann Arbor staging, ALCL99 prognostic groups and age-adjusted International Prognostic Index (IPI). 
Then, for patients with retrospectively collected MDD data available, additional prognostic analysis 
including MDD data together with the above described characteristics was performed. 
Associations between patient characteristics were analyzed with Chi-squared or Fisher’s exact 
tests. The main endpoint for the prognostic factor study was the PFS, defined as the time elapsed 
between the date of biopsy and the date of occurrence of disease progression or relapse. Patients alive 
without treatment failure were censored at the date of last follow-up, which was collected in July 
2018. Patients who died without previous disease progression or relapse were censored at the date of 
death. The OS was also assessed, defined as the time elapsed between the date of biopsy and the date 
of death, whatever the cause. All survival probabilities were estimated using the Kaplan–Meier 
method [20]. Cox model was performed to examine the risk factors affecting the PFS in the 
multivariate analyses, including variable with p < 0.2 in univariate analysis [21]. All p-values were 
two-sided, with a type I error rate fixed at 0.05. Statistical analysis was carried out using the SAS 
statistical program (SAS-PC, version 9.4; SAS Institute Inc., Cary, NC, USA). 
3. Results 
3.1. Patient Characteristics 
Of 529 patients registered in the database, 109 were excluded. Thus, 420 patients were evaluable 
for the current analysis (Figure 1). 
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Figure 1. Flow chart of anaplastic large cell lymphoma (ALCL) patients included in the analysis. 
Among the 420 patients, 256 were males and 164 females (male-to-female ratio, 1.6:1); the median 
age at diagnosis was 11 years (range, 0.8–19.5 years). Overall, 370 patients were randomized into the 
Methotrexate (MTX)-arm of the trial and 205 into the Vinblastine (VLB)-arm. The histological 
diagnosis was based on international panel review or national review of 95% and 5% of patients, 
respectively. The clinical and pathological characteristics of the patients are depicted in Table 1. The 
median follow-up for 420 patients was 9.2 years (range, 0.03–17.9 years). 
Overall, 125 patients experienced disease progression or relapse, and 90 of them (72%) 
underwent a second-line (or further) treatment achieving complete remission (CR). The remaining 35 
patients (38%) never achieved CR and died of tumor progression (n = 24) or due to treatment related 
mortality (TRM) (n = 11). Six other patients died of TRM in their first CR during treatment. Overall 
41 patients died, 35 after a disease progression or relapse. No secondary malignancies were observed 
during the period of long-term follow-up.  
The OS was 91% (SE ± 1%) and 90% (SE ± 1%) at 5 and 10 years, respectively. The PFS was 72% 
(SE ± 2%) and 70% (SE ± 3%) at 5 and 10 years, respectively (Figure 2). 
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Figure 2. The 10-year overall survival (OS) and progression free survival (PFS) were 90% (SE ± 1%) 
(a) and 70% (SE ± 2%) (b), respectively, for the full cohort of 420 patients. 
3.2. Analysis of Prognostic Factors for Risk of Disease Progression or Relapse for the 420 Eligible Patients 
Table 1 details the results of univariate and multivariate analyses of risk of disease progression 
or relapse, considering clinical and pathological characteristics. As was previously demonstrated, the 
type of treatment allocated by randomization did not impact patient outcome; this was not taken into 
account in the main analysis. In univariate analysis, mediastinal involvement (p = 0.03), peripheral 
lymph node involvement (p = 0.02) and the presence of a SC/LH pattern (p < 0.0001) at diagnosis were 
all associated with a worse prognosis (Table 1). These three variables, together with other variables 
that have a p < 0.20 as determined by univariate analysis (St. Jude staging system, defined as stage I 
+ II vs. III + IV, Ann Arbor staging system, defined as 1 + 2 vs. 3 + 4, risk group, and B-symptoms) 
were entered into multivariate analysis. Only SC/LH morphological pattern retained an independent 
association with the risk of disease progression or relapse (hazard ratio = 2.49, p < 0.0001) (Table 1). 
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Table 1. Patient and disease characteristics of the whole study cohort (420 patients). 
Patient characteristics 
#  
Patients 
#  
Events 
10-y PFS 
% 
(SE %) 
Univariate 
p-Value 
Multivariate 
p-Value  
Hazard 
Ratio (95% 
CI) 
Sex  
M 256 73 71 (3) 0.38   
F 164 52 69 (3)    
Age (years) 
<11 206 62 70 (3) 0.87   
≥11 214 63 71 (3)    
LDH (IU/L) 
<361 199 58 72 (3) 0.67   
≥361 221 67 69 (3)    
St. Jude Stage System * 
I + II 109 28 74 (4) 0.17 0.87  
III + IV 311 97 69 (3)    
Ann Arbor Stage System ° 
1 + 2 166 43 74 (4) 0.1 0.73  
3 + 4 25 82 68 (3)    
Risk group ^ 
LR + SR 162 42 75 (4) 0.11 0.15  
HR 258 83 63 (3)    
Age-adjusted IPI (91 mv) 
0–2 263 68 74 (3) 0.02 +   
3 66 26 59 (6)    
B symptoms (5 mv) 
No 185 47 74 (3) 0.08 0.14  
Yes 230 74 68 (3)    
Mediastinum involvement 
No 227 58 75 (3) 0.03 0.14  
Yes 193 67 65 (4)    
Lung lesions 
No 335 98 71 (3) 0.3   
Yes 85 27 68 (5)    
Liver involvement 
No 360 104 71 (2) 0.22   
Yes 60 21 63 (7)    
Spleen involvement 
No 347 101 71 (3) 0.28   
Yes 73 24 68 (6)    
Skin lesions 
No 313 88 72 (3) 0.3   
Yes 107 37 65 (5)    
Soft tissue mass (27 mv) 
No 356 112 68 (3) 0.22   
Yes 37 8 81 (6)    
ENT involvement (10 mv) 
No 405 120 70 (2) 0.61   
Yes 5 1 80 (18)    
Peripheral LN involvement 
No 48 7 88 (5) 0.02 0.08  
Yes 372 118 68 (2)    
Abdominal LN involvement 
No 230 67 71 (3) 0.83   
Yes 190 58 69 (4)    
Visceral (lung, liver, spleen) 
involvement 
No 284 82 72 (3) 0.29   
Yes 136 43 68 (4)    
Kidney and/or pancreas 
lesions 
No 394 117 70 (2) 0.73   
Yes 26 8 69 (9)    
Bone lesions 
No 353 108 70 (3) 0.43   
Yes 67 17 74 (5)    
Bone marrow involvement 
No 379 111 70 (2) 0.62   
Yes 41 14 69 (9)    
ALK immunostaining 
Neg 16 4 75 (11) 0.62   
Pos 404 121 70 (2)    
CD3 immunostaining (98 
mv) 
Neg 268 73 74 (3) 0.04+   
Pos 54 23 56 (7)    
Histological subtype SC/LH 
(24 mv) 
No 275 61 79 (2) <0.0001 <0.0001 
2.49 
(1.71–3.63) 
Yes 121 58 50 (5)    
Events: progression or relapse; PFS: progression free survival; SE: standard error; M: male; F: female; 
LDH: lactate dehydrogenase, median value 361 (range 200–9512 IU/L); LR: low risk; SR: standard risk; 
HR: high risk; IPI: International Prognostic Index; mv: missing value; ENT: ears nose throat; LN: 
lymph nodes; ALK: anaplastic lymphoma kinase; Neg: negative; Pos: positive; ALK: Anaplastic 
Lymphoma Kinase; SC/LH: small cell or lymphohistiocytic; * Patients’ number according to St. Jude 
Stage System: 33 (stage I), 76 (stage II), 270 (stage III), 41 (stage IV); ° Patients’ number according to 
Ann Arbor Stage System: 38 (stage 1), 128 (stage 2), 139 (stage 3), 125 (stage 4); ^ Patients’ number 
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according to LR and SR Risk group: 6 (LR), 156 (SR). + Patient characteristics not included in 
multivariate analysis (despite univariate p-value < 0.20) due to the high number of missing values. 
In particular, the 10-year PFS was 50% (SE ± 5%) for patients with an SC/LH pattern as compared 
to 79% (SE ± 2%) for other morphologies, p < 0.0001 (Figure 3a). Analysis of the statistical associations 
among clinical and pathological prognostic factors for the 420 eligible patients are reported in 
Appendix A. 
 
Figure 3. The 10-year PFS for the full cohort of 420 patients was 50% (SE ± 5%) in the SC/LH subtype 
group and 78% (SE ± 2%) in the non-SC/LH group, p < 0.0001, (a); the 10-year PFS in the subset of 162 
patients with available MDD data was 53% (SE ± 7%) in SC/LH group and 81% (SE ± 4%) in the non-
SC/LH group, p = 0.0006 (b). 
An additional analysis was performed for the subgroup of patients with an age-adjusted IPI 
score and CD3 expression data available. The age-adjusted IPI score and CD3 immunostaining data 
were available for 329/420 (78%) and 322/420 (77%) patients, respectively. Patients stratified for IPI 
score showed a 10-year PFS of 74% (SE ± 3%) and 59% (SE ± 6%) for IPI 0–2 (n = 263) and IPI 3 (n = 
66), respectively (p = 0.02). Analysis of CD3 expression at diagnosis showed a 10-year PFS of 74% (SE 
± 3%) for CD3-negative patients (n = 268) and 56% (SE ± 7%) for CD3-positive patients (n = 54), p = 
0.04. The multivariate analysis, performed in the subgroup of patients for whom IPI score and CD3 
Cancers 2020, 12, 2747 9 of 16 
data were available (n = 232), confirmed the negative prognostic value of an SC/LH pattern (Table 
S2). 
3.3. Analysis of Prognostic Factors for Risk of Disease Progression or Relapse Taking-into-Account MDD 
Analysis 
MDD analysis was conducted for a total of 162 systemic NPM-ALK-positive ALCL patients 
recruited to the ALCL99 trial for whom BM and/or PB samples were available. Qualitative PCR was 
performed by four national groups. Among the 162 patients with BM samples available, 100 had 
matched PB samples. Concordance between BM and PB was high, showing the same results in 82/100 
cases (82%), whereas the test was positive in PB and negative in BM for 11 cases, and negative in PB 
and positive in BM for 7 cases. Clinical, pathological and molecular characteristics of this subset of 
patients are reported in Table 2. The distribution of the clinical and pathological characteristics was 
similar to the distribution of the whole cohort of 420 patients. Among the 162 patients with available 
MDD data, 87 (54%) were MDD-positive and 75 (46%) were MDD-negative. The median follow-up 
of the 162 patients was 9 years (range, 0.03 to 18 years). During follow-up, 46 treatment failures and 
13 deaths were observed. The 10-year PFS for the 162 patients was 72% (SE ± 4%) and the 10-year OS 
was 92% (SE ± 2%). Reported characteristics were assessed by univariate and multivariate analyses 
(Table 2). By univariate analysis, only the SC/LH pattern (p = 0.0006) and MDD-positivity (p = 0.001) 
significantly associated with a higher risk of disease progression or relapse. The multivariate model 
included the St. Jude classification (I + II vs. III + IV), Ann Arbor staging system (1 + 2 vs. 3 + 4), 
mediastinal involvement, soft tissue mass, peripheral lymph node, BM infiltration, CD3 positivity, 
SC/LH pattern and MDD as they had a p-value of less than 0.20 as determined by univariate analysis. 
Both SC/LH morphological pattern and MDD positivity were significantly associated with the risk of 
failure as assessed by multivariate analysis, with a hazard ratio = 2.4, p = 0.009, and a hazard ratio = 
2.15, p = 0.038, respectively. 
Table 2. Patient and disease characteristics of the 162 patients with minimal disseminated disease 
data available. 
Patient characteristics 
# 
Patients 
# 
Events 
10-y 
PFS % 
(SE %) 
Univariate p-
Value 
Multivariate p-
Value 
Hazard 
Ratio (95% 
CI) 
Sex 
M 103 27 73 (4) 0.44   
F 59 19 68 (6)    
Median age (years) 
<10 75 23 69 (5) 0.73   
≥10 87 23 74 (5)    
Median LDH (IU/L) 
<375 81 25 70 (5) 0.63   
≥375 81 21 73 (5)    
St. Jude Staging System 
* 
I + II 35 6 83 (6) 0.1 0.39  
III + IV 127 40 69 (4)    
Ann Arbor Staging 
System ° 
1 + 2 55 12 78 (6 0.14 0.93  
3 + 4 107 34 68 (5)    
Risk group ^ 
LR + SR 62 15 77 (5) 0.31   
HR 100 31 68 (5)    
Age-adjusted IPI (53 
mv) 
0–2 84 21 76 (5) 0.48   
3 25 8 67 (10)    
B symptoms (2 mv) 
No 64 17 73 (6) 0.61   
Yes 96 28 71 (5)    
Mediastinum 
involvement 
No 84 20 77 (5) 0.13 0.26  
Yes 78 26 65 (5)    
Lung involvement 
No 129 36 73 (4) 0.45   
Yes 33 10 67 (9)    
Liver involvement 
No 143 41 72 (4) 0.93   
Yes 19 5 72 (11)    
Spleen involvement  
No 133 39 71 (4) 0.8   
Yes 29 7 74 (8)    
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Skin lesions 
No 119 30 75 (4) 0.21   
Yes 43 16 63 (7)    
Soft tissue mass 
No 132 42 68 (4) 0.11 0.28  
Yes 16 2 88 (8)    
ENT involvement (4 
mv) 
No 158 44 72 (4) -   
Yes 0 0 -    
Peripheral LN 
involvement 
No 20 2 90 (7) 0.06 0.11  
Yes 142 44 69 (4)    
Abdominal LN 
involvement 
No 90 25 72 (5) 0.86   
Yes 72 21 71 (5)    
Visceral (lung, liver, 
spleen) involvement 
No 111 31 73 (4) 0.55   
Yes 51 15 69 (7)    
Kidney + pancreas 
lesions 
No 153 44 71 (4) 0.69   
Yes 9 2 78 (14)    
Bone lesions 
No 128 39 70 (4) 0.23   
Yes 34 7 79 (7)    
Bone marrow 
involvement 
No 152 41 73 (4) 0.14 0.74  
Yes 10 5 50 (16)    
ALK immuno-staining 
Neg 0 0 - -   
Pos 162 46 72 (4)    
CD3 immunostaining 
(22 mv) 
Neg 83 31 72 (4) 0.08 0.25  
Pos 17 13 55 (9)    
Histological subtype 
SC/LH (8 mv) 
No 95 19 81 (4) 0.0006 0.009 
2.4 
(1.23–4.66) 
Yes 59 27 53 (7)    
MDD 
Neg 75 12 83 (4) 0.001 0.038 
2.15 
(1.04–4.64) 
Pos 87 34 62 (5)    
Events: progression or relapse; PFS: progression free survival; SE: standard error; M: male; F: female; 
LDH: lactate dehydrogenase; LR: low-risk; SR: standard-risk; HR: high-risk; IPI: International 
Prognostic Index; mv: missing value; ENT: ears nose throat; LN: lymph nodes; ALK: anaplastic 
lymphoma kinase; SC/LH: small cell or lymphohistiocytic; Neg: negative; Pos: positive; MDD: 
minimal disseminated disease; * Patients’ number according to St. Jude Stage System: 11 (stage I), 24 
(stage II), 115 (stage III), 12 (stage IV); ° Patients’ number according to Ann Arbor Stage System: 13 
(stage 1), 42 (stage 2), 51 (stage 3), 56 (stage 4); ^ Patients’ number according to LR and SR Risk Group: 
3 (LR), 59 (SR). 
The 10-year PFS was 53% (SE ± 7%) in the SC/LH group and 81% (SE ± 4%) in the non-SC/LH 
group, p = 0.0006 (Figure 3b). The 10-year PFS according to MDD stratification was 62% (SE ± 5%) for 
the MDD positive group and 83% (SE ± 4%) for the MDD negative group, p = 0.001 (Figure 4). Analysis 
of the statistical associations among clinical, pathological and biological prognostic factors for the 162 
patients with MDD evaluation are reported in Appendix A. 
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Figure 4. The 10-year PFS according to MDD stratification was 62% (SE ± 5%) for the MDD positive 
patients and 83% (SE ± 4%) for the MDD negative patients, p = 0.001. 
In addition, in an attempt to highlight different biological/pathological (bp) risk groups, a 
combination of the two independent prognostic factors identified by multivariate analysis (MDD and 
SC/LH pattern) was tested. Thus, patients were stratified into 3 new risk groups: (1) a high-risk group 
(bpHR) including MDD-positive patients and SC/LH morphological pattern (35/154 patients, 23%); 
(2) a low-risk group (bpLR) including MDD-negative patients without SC/LH pattern (45/154 
patients, 29%); (3) an intermediate-risk group (bpIR) including all other patients with one of the two 
factors (74/154 patients, 48%). Univariate analysis showed a 10-year PFS of 40% (SE ± 8%), 75% (SE ± 
5%) and 86% (SE ± 5%) for bpHR (n = 35), bpIR (n = 74) and bpLR (n = 45), respectively (p < 0.0001) 
(Figure 5). The 10-year OS analysis according to the bp risk groups did not show any statistical 
differences among the 3 groups (Figure S1). 
 
Figure 5. The 10-year PFS was 40% (SE ± 8%), 75% (SE ± 5%) and 86% (SE ± 5%) for bpHR (n = 35), 
bpIR (n = 74) and bpLR (n = 45), respectively (p < 0.0001).  
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4. Discussion 
We report the long-term follow-up and explored potential prognostic factors for relapse in a 
large cohort of 420 children, adolescents and young adults with systemic ALCL treated 
homogeneously within the international ALCL99 trial across 10 countries between 1999 and 2006. 
The randomized ALCL99 trial demonstrated that the dose and mode of administration of high dose 
MTX in the MTX-arm, for SR and HR patients and the addition of VBL to the ALCL99 backbone in 
the VBL-arm, for HR patients, did not impact the risk of failure [4,5]. These findings provide the 
unique opportunity to describe and analyze prognostic factors in the largest cohort of prospectively 
collected data from patients with this rare disease and a very long follow-up of on average 10 years. 
The 2-year survival analysis previously reported for the MTX-arm (OS of 92.5% and EFS of 74.1%) [4] 
and for the VBL-arm (OS of 94% and EFS of 71%) [5] were stable over time. Our analysis confirms a 
risk of relapse of about 30% and shows that ALCL patients had a reasonable chance of rescue at 
relapse reaching an OS of about 90%. PFS and OS were similar at 5 and 10 years from diagnosis, with 
very rare events observed after the fifth year. Of note, no secondary malignancies were registered. In 
the present analysis, patients with HR criteria, as defined in the ALCL99 trial, unexpectedly did not 
have a higher risk of relapse. Although our analysis confirmed by univariate analysis the negative 
prognostic value of mediastinal involvement (p = 0.03), we have not been able to confirm the negative 
prognostic value of skin and/or visceral involvement. None of the other clinical characteristics were 
associated with the risk of relapse as determined by univariate analysis, except for peripheral lymph 
node involvement (p = 0.02), age-adapted IPI score 3 (p = 0.02) and CD3 positivity (p = 0.04); these last 
two variables unfortunately could not be tested in the global multivariate analysis due to high 
number of missing data. It was observed that lymph nodes were involved in almost 90% of patients; 
the remaining 48 patients without lymph node involvement at diagnosis, and with better prognosis, 
were patients with rare sites of presentation, mostly soft tissue masses (40%) or bone lesions (33%), 
independent of the overall stage.  
Our analysis has confirmed the negative prognostic value of an SC/LH pattern as previously 
reported by Lamant in 2011 based on a preliminary histological analysis of ALCL99 trial data [12]. 
Patients with SC/LH pattern could be hypothesized to have low levels of immune activation against 
tumor cells since the presence of the SC/LH pattern has been shown to be associated with low anti-
ALK antibody titers at initial diagnosis [15]. Even though the presence of an SC/LH pattern has been 
shown to be associated with a higher risk of failure in several studies [12,14,16], this criterium is not 
used to stratify treatment as it requires centralized pathology review and further international testing 
to evaluate its reproducibility. In fact, the concordance between national and international reviews 
was good but not excellent (κ index equal to 0.67), suggesting that highly reproducible specific criteria 
have yet to be defined [12]. In addition, identifying biomarkers associated with this subtype might 
help to implement a more precise definition and tailored treatment.  
MDD data were not available for all ALCL patients included in the ALCL99 trial since MDD 
analysis was not mandatory and was only performed in a few select laboratories of the participating 
countries. Harmonization and quality control of MDD methods had been introduced among these 
laboratories facilitating the inclusion of all data into a common analysis. The multivariate analysis 
performed on the subgroup of 162 ALCL patients with available MDD results, confirmed that both 
MDD-positivity and the presence of a SC/LH pattern were independently associated with relapse. 
This allowed for the definition of three risk groups: the bpHR group, including MDD-positive 
patients with SC/LH pattern, accounting for 29% of patients, had a worse prognosis with a 10-year 
PFS of 40% compared to the bpLR group, including MDD-negative patients without the SC/LH 
pattern, with a 10-year PFS of 86%. The bpIR group, including all other patients, showed a 10-year 
PFS of 75%. The 10-year OS according to the bp risk groups did not show any statistical difference, 
confirming that the salvage therapies are highly effective for pediatric patients affected by ALCL. 
Several other risk factors for ALCL such as minimal residual disease (MRD) or anti ALK-antibody 
titers have previously been reported by other international collaborative groups [16,22–24]. The 
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number of patients with available data regarding MRD or ALK-antibodies in the current analysis was 
too small to allow for analysis including these parameters.  
Anyway, the characterization of biological/pathological groups of pediatric patients with poor 
outcome could accelerate the availability of well-known targeted therapies also for the first line 
treatment during childhood. In fact, to date, the experience in pediatric age of promising drugs like 
anti-CD30 antibody-drug conjugate, last-generation ALK-inhibitors and immune check-point 
inhibitors, is still limited to clinical trials or ad hoc off-label use [24]. 
In conclusion, the results described here have allowed us to propose risk stratification 
parameters for new international trials for the treatment of children, adolescents and young adults 
affected by ALCL based on MDD results and SC/LH morphological pattern. In particular, in this 
scenario, high-risk patients who are MDD positive at diagnosis could benefit more from the last 
generation targeted drugs. 
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Appendix A 
Appendix A.1. Analysis of the Statistical Associations Among Clinical and Pathological Prognostic Factors for the 420 
Eligible Patients 
Mediastinal involvement, peripheral lymph nodes and SC/LH pattern showed a significant association 
with the risk of disease progression or relapse when assessed by univariate analysis. 
Compared to patients without mediastinal involvement (227 patients), patients with mediastinal disease 
showed significantly higher levels of LDH above the median value (107/227 cases, 47% vs. 114/193 cases, 59%; p 
= 0.015), more often B-symptoms (90/227 cases, 40% vs. 140/188 cases, 75%; p < 0.0001), involvement of peripheral 
lymph nodes (192/227 cases, 85% vs. 180/193 cases, 93%; p = 0.005), visceral involvement (lung, liver or spleen, 
40/227 cases, 18% vs. 96/193 cases, 50%; p < 0.0001) and BM disease (14/227 cases, 6% vs. 27/193 cases, 14%; p = 
0.02). 
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Patients with peripheral lymph node involvement displayed HR characteristics (22/48 cases, 46% vs. 
236/372 cases, 63%; p = 0.02), but were less often associated with soft tissue lesions (15/45, 33%, vs. 22/348, 6%; p 
< 0.0001) or bone involvement (19/48, 40% vs. 48/372, 13%, p < 0.0001), compared to patients without peripheral 
lymph node involvement.  
The SC/LH pattern was significantly associated with mediastinal involvement (114/275 cases, 42% vs. 
65/121, 54%; p = 0.02) and skin lesions (58/275, 21% vs. 46/121, 38%, p = 0.0004). In addition, the SC/LH pattern 
was associated with a higher LDH value (131/275 cases, 48% vs. 74/121 cases, 61%; p = 0.01), HR group (150/275 
cases, 55% vs. 92/121 cases, 76%; p < 0.0001) and an absence of liver involvement (31/275 cases, 11% vs. 27/121 
cases, 22%; p = 0.004) or visceral involvement (80/275 cases, 29% vs. 50/121 cases, 41%; p = 0.02). 
Appendix A.2. Analysis of the Statistical Associations among Clinical, Pathological and Biological Prognostic Factors 
for the 162 Patients with MDD Evaluation 
By univariate analysis, only the SC/LH pattern and MDD-positivity significantly associated with a higher 
risk of disease progression or relapse. As for the whole group of patients, SC/LH pattern was associated with 
mediastinal involvement (38/95 cases, 40% vs. 35/59 cases, 59%; p = 0.02) and with HR characteristics (51/95 cases, 
54% vs. 44/59 cases, 75%; p = 0.009). MDD was significantly associated with B-symptoms (31/75 cases, 41% vs. 
65/85 cases, 76%; p < 0.0001), mediastinal involvement (29/75 cases, 39% vs. 49/87 cases, 56%; p = 0.03) and visceral 
involvement (17/75 cases, 23% vs. 34/87 cases, 39%; p = 0.03). No association between MDD and skin involvement 
was detected (p = 0.08). Consequently, MDD positivity strongly associated with the clinical HR group (37/75 
cases, 49% vs. 63/87, 72%; p = 0.002) and with an increased LDH level (32/75 cases, 43% vs. 53/87, 61%; p = 0.02). 
In addition, MDD positivity was related to morphological BM involvement (1/75 cases, 1% vs. 9/87, 10%; p = 
0.02). By contrast, we did not observe any relationship between MDD positivity and SC/LH pattern (24/69 cases, 
35% vs. 35/85, 41%; p = 0.42). 
References 
1. Burkhardt, B.; Zimmermann, M.; Oschlies, I.; Niggli, F.; Mann, G.; Parwaresch, R.; Riehm, H.; Schrappe, 
M.; Reiter, A.; The BFM Group. The impact of age and gender on biology, clinical features and treatment 
outcome of non-Hodgkin lymphoma in childhood and adolescence. Br. J. Haematol. 2005, 131, 39–49, 
doi:10.1111/j.1365-2141.2005.05735.x. 
2. Delsol, G. The 2008 WHO lymphoma classification. Ann. Pathol. 2008, 28, S20–S24, 
doi:10.1016/j.annpat.2008.09.002. 
3. Le Deley, M.C.; Reiter, A.; Williams, D.; Delsol, G.; Oschlies, I.; McCarthy, K.; Zimmermann, M.; Brugières, 
L. Prognostic factors in childhood anaplastic large cell lymphoma: Results of a large European intergroup 
study. Blood 2008, 111, 1560–1566, doi:10.1182/blood-2007-07-100958. 
4. Brugières, L.; Le Deley, M.C.; Rosolen, A.; Williams, D.; Horibe, K.; Wrobel, G.; Mann, G.; Zsiros, J.; 
Uyttebroeck, A.; Marky, I.; et al. Impact of the methotrexate administration dose on the need for intrathecal 
treatment in children and adolescents with anaplastic large-cell lymphoma: Results of a randomized trial 
of the EICNHL Group J. Clin. Oncol. 2009, 27, 897–903, doi:10.1200/JCO.2008.18.1487. 
5. Le Deley, M.C.; Rosolen, A.; Williams, D.M.; Horibe, K.; Wrobel, G.; Attarbaschi, A.; Zsiros, J.; Uyttebroeck, 
A.; Marky, I.M.; Lamant, L.; et al. Vinblastine in children and adolescents with high-risk anaplastic large-
cell lymphoma: Results of the randomized ALCL99-vinblastine trial. J. Clin. Oncol. 2010, 28, 3987–3993, 
doi:10.1200/JCO.2010.28.5999. 
6. Brugières, L.; Deley, M.C.; Pacquement, H.; Meguerian-Bedoyan, Z.; Terrier-Lacombe, M.J.; Robert, A.; 
Pondarré, C.; Leverger, G.; Devalck, C.; Rodary, C.; et al. CD30(+) anaplastic large-cell lymphoma in 
children: Analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric 
Oncology. Blood 1998, 92, 3591–3598. 
7. Alexander, S.; Kraveka, J.M.; Weitzman, S.; Lowe, E.; Smith, L.; Lynch, J.C.; Chang, M.; Kinney, M.C.; 
Perkins, S.L.; Laver, J.; et al. Advanced stage anaplastic large cell lymphoma in children and adolescents: 
Results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: A 
report from the children’s oncology group. Pediatr. Blood Cancer 2014, 61, 2236–2242, 
doi:10.1002/pbc.25187.Epub 2014 Aug 23. 
Cancers 2020, 12, 2747 15 of 16 
8. Lowe, E.J.; Sposto, R.; Perkins, S.L.; Gross, T.G.; Finlay, J.; Zwick, D.; Abromowitch, M. Intensive 
chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of 
Children’s Cancer Group Study 5941. Pediatr. Blood Cancer 2009, 52, 335–339, doi:10.1002/pbc.21817. 
9. Seidemann, K.; Tiemann, M.; Schrappe, M.; Yakisan, E.; Simonitsch, I.; Janka-Schaub, G.; DorffelW.; 
Zimmermann, M.; Mann, G.; Gadner, H.; et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy 
is efficacious treatment for pediatric anaplastic large cell lymphoma: A report of the Berlin-Frankfurt-
Münster Group Trial NHL-BFM 90. Blood 2001, 15, 3699–3706, doi:10.1182/blood.v97.12.3699. 
10. Williams, D.M.; Hobson, R.; Imeson, J.; Gerrard, M.; McCarthy, K.; Pinkerton, C.R. Anaplastic large cell 
lymphoma in childhood: Analysis of 72 patients treated on The United Kingdom Children’s Cancer Study 
Group chemotherapy regimens. Br. J. Haematol. 2002, 117, 812–820, doi:10.1046/j.1365-2141.2002.03482.x. 
11. Rosolen, A.; Pillon, M.; Garaventa, A.; Burnelli, R.; d’Amore, E.S.; Giuliano, M.; Comis, M.; Cesaro, S.; 
Tettoni, K.; Moleti, M.L.; et al. Anaplastic large cell lymphoma treated with a leukemia-like therapy: Report 
of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer 2005, 
104, 2133–2140, doi:10.1002/cncr.21438. 
12. Lamant, L.; McCarthy, K.; d’Amore, E.; Klapper, W.; Nakagawa, A.; Fraga, M.; Maldyk, J.; Simonitsch-
Klupp, I.; Oschlies, I.; Delsol, G.; et al. Prognostic impact of morphologic and phenotypic features of 
childhood ALK-positive anaplastic large-cell lymphoma: Results of the ALCL99 study. J. Clin. Oncol. 2011, 
29, 4669–4676, doi:10.1200/JCO.2011.36.5411. 
13. Mussolin, L.; Pillon, M.; d’Amore, E.S.; Santoro, N.; Lombardi, A.; Fagioli, F.; Zanesco, L.; Rosolen, A. 
Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell 
lymphoma. Leukemia 2005, 19, 1643–1647, doi:10.1038/sj.leu.2403888. 
14. Damm-Welk, C.; Busch, K.; Burkhardt, B.; Schieferstein, J.; Viehmann, S.; Oschlies, I.; Klapper, W.; 
Zimmermann, M.; Harbott, J.; Reiter, A.; et al. Prognostic significance of circulating tumor cells in bone 
marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-
positive anaplastic large-cell lymphoma. Blood 2007, 110, 670–677, doi:10.1182/blood-2007-02-066852. 
15. Ait-Tahar, K.; Damm-Welk, C.; Burkhardt, B.; Zimmermann, M.; Klapper, W.; Reiter, A.; Pulford, K.; 
Woessmann, W. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic 
lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. 
Blood 2010, 115, 3314–3319, doi:10.1182/blood-2009-11-251892. 
16. Mussolin, L.; Damm-Welk, C.; Pillon, M.; Zimmermann, M.; Franceschetto, G.; Pulford, K.; Reiter, A.; 
Rosolen, A.; Woessmann, W. Use of minimal disseminated disease and immunity to NPM-ALK antigen to 
stratify ALK-positive ALCL patients with different prognosis. Leukemia 2013, 27, 416–422, 
doi:10.1038/leu.2012.205. 
17. Carbone, P.P.; Kaplan, H.S.; Musshoff, K.; Smithers, D.W.; Tubiana, M. Report of the Committee on 
Hodgkin’s Disease Staging Classification. Cancer Res. 1971, 31, 1860–1861. 
18. Murphy, S.B. Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: 
Dissimilarities from lymphomas in adults. Semin. Oncol. 1980, 7, 332–339. 
19. Del Baldo, G.; Abbas, R.; Woessmann, W.; Horibe, K.; Pillon, M.; Burke, A.; Beishuizen, A.; Rigaud, C.; Le 
Deley, M.C.; Lamant, L.; et al. Neuro-meningeal relapse in anaplastic large-cell lymphoma: Incidence, risk 
factors and prognosis—A report from the European intergroup for childhood non-Hodgkin lymphoma. 
Br. J. Haematol. 2020, doi:10.1111/bjh.16755. 
20. Kaplan, E.L.; Meier, P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc. 1958, 53, 
457–481. 
21. Cox, D.R. Regression models and life tables. J. R. Stat. Soc. 1972, 34, 187–220. 
22. Damm-Welk, C.; Mussolin, L.; Zimmermann, M.; Pillon, M.; Klapper, W.; Oschlies, I.; D’Amore, E.S.G.; 
Reiter, A.; Woessmann, W.; Rosolen, A. Early Assessment of Minimal Residual Disease Identifies Patients 
at Very High Relapse Risk in NPM-ALK-positive Anaplastic Large-Cell Lymphoma. Blood 2014, 123, 334–
337, doi:10.1182/blood-2013-09-526202. 
  
Cancers 2020, 12, 2747 16 of 16 
23. Larose, H.; Burke, G.A.A.; Lowe, E.J.; Turner, S.D. From bench to bedside: The past, present and future of 
therapy for systemic paediatric ALCL, ALK. Br. J. Haematol. 2019, 185, 1043–1054, doi:10.1111/bjh.15763. 
24. Turner, S.D.; Lamant, L.; Kenner, L.; Brugières, L. Anaplastic large cell lymphoma in paediatric and young 
adult patients. Br. J. Haematol. 2016, 173, 560–572, doi:10.1111/bjh.13958. 
 
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
